Form 4: Verastem CFO Daniel Calkins Receives Stock Awards
SEC Form 4 Filing
Verastem's Chief Financial Officer, Daniel Calkins, was granted 38,800 shares of common stock on January 10, 2025, under the company's equity incentive plan.
Summary
- Daniel Calkins, the Chief Financial Officer of Verastem, Inc., received 38,800 shares of common stock on January 10, 2025.
- These shares were granted as restricted stock units (RSUs) under the company's Amended and Restated 2021 Equity Incentive Plan.
- The RSUs vest in three equal installments on the first three anniversaries of the grant date, January 10, 2025, with full vesting occurring on January 10, 2028.
- Vesting is contingent upon Calkins' continued employment or service to Verastem.
Sentiment
Score: 7
Explanation: The sentiment is neutral to positive as it reflects standard executive compensation practices. The vesting schedule promotes long-term alignment, which is generally viewed favorably.
Positives
- The equity grant aligns the CFO's interests with those of the shareholders, incentivizing him to contribute to the company's long-term success.
- The vesting schedule encourages continued service and commitment from the CFO.
Risks
- If Daniel Calkins leaves Verastem before January 10, 2028, he will forfeit the unvested RSUs.
Future Outlook
The document does not contain specific forward-looking statements beyond the vesting schedule of the RSUs.
Industry Context
Equity grants are a common practice in the biotechnology industry to attract and retain key executives.
Comparison to Industry Standards
- Equity compensation packages for CFOs in biotech companies typically include a mix of stock options, restricted stock units, and performance-based awards.
- The size and vesting schedule of the RSU grant are likely benchmarked against similar companies in the pharmaceutical industry to ensure competitiveness.
Stakeholder Impact
- Shareholders may view the equity grant as a positive sign, indicating confidence in the CFO's ability to contribute to the company's success.
- Employees may see the grant as a sign of the company's commitment to its leadership team.
Key Dates
| Date | Description |
|---|---|
| 01/10/2025 | Date of earliest transaction and RSU Grant Date |
| 01/10/2026 | First vesting date for 33.3% of the RSUs |
| 01/10/2027 | Second vesting date for 33.3% of the RSUs |
| 01/10/2028 | Final vesting date for the remaining RSUs |
| 01/14/2025 | Date of signature |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.